Temperamental activity and epidermal growth factor A61G polymorphism in Finnish adults

Neuropsychobiology

Volumn 56, Issue 4, 2008, Pages 208-212

  Puttonen, Sampsa ^a,c   Keltikangas Järvinen, Liisa ^a   Elovainio, Marko ^b   Kivimäki, Mika ^e   Rontu, Riikka ^d   Lehtimäki, Terho ^d  

^a UNIVERSITY OF HELSINKI   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Activity temperament; Epidermal growth factor; Genotype

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR A61G; UNCLASSIFIED DRUG;

ACTIMETRY; ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; EGF GENE; ELECTROMYOGRAPHY; FEMALE; FINLAND; GENE; GENETIC ASSOCIATION; GENETIC DIFFERENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR ACTIVITY; NERVOUS SYSTEM FUNCTION; POPULATION RESEARCH; PRIORITY JOURNAL; SELF REPORT; TEMPERAMENT;

ADULT; CARDIOVASCULAR DISEASES; EPIDERMAL GROWTH FACTOR; FEMALE; FINLAND; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; TEMPERAMENT;

EID: 42449155376     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000122266     Document Type: Article

References (29)

1. Buss AH, Plomin R: Temperament Early Developing Personality Traits. Hillsdale, Erlbaum, 1984.
2. Buss AH: The EAS theory of temperament; in Strelau J, Angleitner A (eds): Explorations in Temperament: International Perspectives on Theory and Measurement Perspectives on Individual Differences. New York, Plenum Press, 1991, pp 43-60.
3. Ravaja N, Katainen S, Keltikangas-Järvinen L: Perceived difficult temperament, hostile maternal child-rearing attitudes and insulin resistance syndrome precursors among children: a 3-year follow-up study. Psychother Psychosom 2001;70: 66-77.
4. Ravaja N, Keltikangas-Järvinen L: Temperament and metabolic syndrome precursors in children: a three-year follow-up. Prev Med 1995;24:518-527.
5. Lazar LM, Blum M: Regional distribution and developmental expression of epidermal growth factor and transforming growth factor-alpha mRNA in mouse brain by a quantitative nuclease protection assay. J Neurosci 1992;12:1688-1697.
6. Carpenter G, Cohen S: Epidermal growth factor. Ann Rev Biochem 1979;48:193-216.
7. Alexi T, Hefti F: Trophic actions of transforming growth factor alpha on mesencephalic dopaminergic neurons developing in culture. Neuroscience 1993;55:903-918.
8. Casper D, Roboz GJ, Blum M: Epidermal growth factor and basic fibroblast growth factor have independent actions on mesencephalic dopamine neurons in culture. J Neurochem 1994;62:2166-2177.
9. Ferrari G, Toffano G, Skaper SD: Epidermal growth factor exerts neuronotrophic effects on dopaminergic and GABAergic CNS neurons: comparison with basic fibroblast growth factor. J Neurosci Res 1991;30:493-497.
10. Missale C, Castelletti L, Boroni F, Memo M, Spano P: Epidermal growth factor induces the functional expression of dopamine receptors in the GH3 cell line. Endocrinology 1991;128:13-20.
11. Sibilia M, Steinbach JP, Stingl L, Aguzzi A, Wagner EF: A strain-independent postnatal neurodegeneration in mice lacking the EGF receptor. EMBO J 1998;17:719-731.
12. Moldin SO, Gottesman II: At issue: genes, experience, and chance in schizophrenia - positioning for the 21st century. Schizophr Bull 1997;23:547-561.
13. Futamura T, Toyooka K, Iritani S, Niizato K, Nakamura R, Tsuchiya K, Someya T, Kakita A, Takahashi H, Nawa H: Abnormal expression of epidermal growth factor and its receptor in the forebrain and serum of schizophrenic patients. Mol Psychiatry 2002;7:673-682.
14. Hänninen K, Katila H, Anttila S, Rontu R, Maaskola J, Hurme M, Lehtimäki T: Epidermal growth factor A61G polymorphism is associated with the age of onset of schizophrenia in male patients. J Psychiatr Res 2007;41:8-14.
15. Lee KY, Ahn YM, Joo EJ, Joo YH, Chang JS, Yoo HY, Kim YS: Partial evidence of an association between epidermal growth factor A61G polymorphism and age at onset in male schizophrenia. Neurosci Res 2006;56:356-362.
16. Futamura T, Kakita A, Tohmi M, Sotoyama H, Takahashi H, Nawa H: Neonatal perturbation of neurotrophic signaling results in abnormal sensorimotor gating and social interaction in adults: implication for epidermal growth factor in cognitive development. Mol Psychiatry 2003;8:19-29.
17. Mizuno M, Malta RS Jr, Nagano T, Nawa H: Conditioned place preference and locomotor sensitization after repeated administration of cocaine or methamphetamine in rats treated with epidermal growth factor during the neonatal period. Ann NY Acad Sci 2004;1025:612-618.
18. Tohmi M, Tsuda N, Mizuno M, Takei N, Frankland PW, Nawa H: Distinct influences of neonatal epidermal growth factor challenge on adult neurobehavioral traits in four mouse strains. Behav Genet 2005;35:615-629.
19. Pezzoli G, Zecchinelli A, Ricciardi S, Burke RE, Fahn S, Scarlato G, Carenzi A: Intraventricular infusion of epidermal growth factor restores dopaminergic pathway in hemiparkinsonian rats. Mov Disord 1991;6:281-287.
20. Shahbazi M, Pravica V, Nasreen N, Fakhoury H, Fryer AA, Strange RC, Hutchinson PE, Osborne JE, Lear JT, Smith AG, Hutchinson IV: Association between functional polymorphism in EGF gene and malignant melanoma. Lancet 2002;359:397-401.
21. Ebstein RP, Belmaker RH: Saga of an adventure gene: novelty seeking, substance abuse and the dopamine d4 receptor (d4dr) exon III repeat polymorphism. Mol Psychiatry 1997;2:381-384.
22. Åkerblom HK, Uhari M, Pesonen E, Dahl M, Kaprio EA, Nuutinen EM, Pietikäinen M, Salo MK, Aromaa A, Kannas L, Keltikangas-Järvinen L, Kuusela V, Räsänen L, Rönnemaa T, Knip M, Telama R, Välimäki I, Pyörälä K, Viikari J: Cardiovascular risk in young Finns. Ann Med 1991;23:35-40.
23. Livak KJ: Allelic discrimination using fluorogenic probes and the 5′ nuclease assay. Genet Anal 1999;14:143-149.
24. Kramer A, Yang FC, Snodgrass P, Li X, Scammell TE, Davis FC, Weitz CJ: Regulation of daily locomotor activity and sleep by hypothalamic EGF receptor signaling. Science 2001;294:2511-2515.
25. Boillee S, Cadusseau J, Coulpier M, Grannec G, Junier MP: Transforming growth factor alpha: a promoter of motoneuron survival of potential biological relevance. J Neurosci 2001;21:7079-7088.
26. Nieoullon A, Coquerel A: Dopamine: a key regulator to adapt action, emotion, motivation and cognition. Curr Opin Neurol 2003;16(suppl 2):S3-S9.
27. Adamson ED, Meek J: The ontogeny of epidermal growth factor receptors during mouse development. Dev Biol 1984;103:62-70.
28. Nishii K, Matsushita N, Sawada H, Sano H, Noda Y, Mamiya T, Nabeshima T, Nagatsu I, Hata T, Kiuchi K, Yoshizato H, Nakashima K, Nagatsu T, Kobayashi K: Motor and learning dysfunction during postnatal development in mice defective in dopamine neuronal transmission. J Neurosci Res 1998;54:450-464.
29. Kobayashi K, Sano H: Dopamine deficiency in mice. Brain Dev 2000;22(suppl 1):S54-S60.